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The serum amyloid A (SAA) family of secreted proteins 
is encoded by multiple genes that display a high degree of 
homology in mammals. SAAs can be divided into two main 
classes based on their responsiveness to inflammatory stim-
uli. The “acute phase” SAAs are major acute phase reac-
tants whose serum concentrations increase by 1,000-fold or 
more in response to tissue injury and infection. In contrast, 
“constitutive” SAA is minimally induced and is present in 
relatively low concentrations in plasma (1, 2). The genes 
for the two major acute phase human SAAs, Saa1 and Saa2, 
correspond to mouse Saa1.1 and Saa2.1. Mice express a 
third acute phase SAA, SAA3, which is not expressed in 
humans due to the presence of a premature stop codon. 
Both human SAA4 and mouse SAA4 are constitutive SAAs. 
Circulating SAA is produced and secreted primarily by the 
liver and is present in plasma mainly associated with HDL 
(1, 2). However, expression of extrahepatic SAA is also 
found in inflamed tissues, such as adipose tissue in obesity 
(3), atherosclerotic lesions (4, 5), synovial tissue in rheu-
matoid arthritis (6), various carcinomas (7), and lung tis-
sue in chronic obstructive pulmonary disease (8).
Increased circulating SAA has been associated with sev-
eral inflammatory diseases, including obesity (3), type 2 
diabetes (9), atherosclerosis (10, 11), abdominal aortic an-
eurysms (12), pulmonary disease (13), and cancer (7), and 
emerging research implies that SAA plays a pathogenic 
role in the development of these conditions. Thus, under-
standing the pathways by which SAA levels and activity are 
regulated is critical. SAA has been shown to exert a number 
of biological activities consistent with a role in innate 
immunity, including leukocyte chemotaxis (14, 15), inflam-
matory cytokine induction (16–18), activation of the 
NLRP3 inflammasome (19), and upregulation of genes 
involved in extracellular matrix remodeling, including 
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transforming growth factor- (TGF-) (20) and matrix me-
talloproteinases (21).
The majority of SAA in the circulation is lipoprotein-
associated and not in a lipid-free form (22), and accumu-
lating evidence indicates that the lipidation status of SAA is 
a critical factor governing its function. For example, only 
lipid-free SAA, but not HDL-associated SAA, stimulates 
macrophages to express granulocyte colony stimulating 
factor (G-CSF) in vitro (23). The chemoattractant activity 
of SAA is also dampened by its association with HDL (24). 
Similarly, association with HDL inhibits the ability of SAA 
to stimulate reactive oxygen species generation and NLRP3 
inflammasome activation in macrophages (19). Plasma 
SAA is cleared more rapidly than the other major HDL 
apolipoproteins, apoA-I and apoA-II (25), suggesting that 
SAA dissociates from HDL more readily compared with 
apoA-I and apoA-II. Despite the growing recognition that 
SAA lipidation and delipidation may be key regulators of 
its biological activity, the processes involved in determining 
its lipidation state have not been well defined. In this study, 
we investigated SAA lipidation by hepatocytes and how 
such lipidation relates to the formation of nascent HDL. 




C57BL/6 mice and apoA-I-deficient mice were purchased from 
the Jackson Laboratory. Mice deficient in both of the two major 
acute phase SAA isoforms, SAA1.1 and SAA2.1 (SAA1.1/2.1-
DKO) were bred to obtain a >99.9% C57BL/6 background using 
the Jackson Laboratory Speed Congenic Service as previously 
described (26). Mice deficient in SAA1.1, SAA2.1, and SAA3 
(SAA1.1/2.1/3-TKO) were obtained by deleting the Saa3 gene in 
SAA1.1/2.1-DKO mice using CRISPR Genome Editing technol-
ogy (27). Liver-specific ABCA1-KO mice (albumin Cre+, ABCA-
1flox/flox) were provided by Dr. John S. Parks, Wake Forest 
University (28). Scavenger receptor class B type I (SR-BI)/ and 
SR-BI+/+ mice were obtained from Dr. Xiang-An Li, University of 
Kentucky (29). Induction of hepatic SAA expression was achieved 
by injecting Escherichia coli lipopolysaccharide (LPS; 0111:B4; 
Sigma-Aldrich, St. Louis, MO) intraperitoneally into C57BL/6 
mice (1 g/g body weight) or by intravenous injection of 1 × 1011 
particles of an adenoviral vector expressing SAA (AdSAA) into 
SAA1.1/2.1/3-TKO mice. Where indicated, an empty vector, Ad-
Null, was used as negative control for adenovirus studies. Animals 
were housed in micro-isolator cages and maintained on a 14 h 
light/10 h dark cycle. Mice were provided with normal chow diet 
and water ad libitum. All studies were performed in accordance 
with the Public Health Service Policy on Humane Care and Use of 
Laboratory Animals and with the approval of the University of 
Kentucky Institutional Animal Care and Use Committee.
Primary hepatocyte culture
Primary hepatocytes were isolated from untreated C57BL/6 
mice at 6 or 24 h after LPS or adenoviral vector injection, respec-
tively, using a two-step perfusion method as described previously 
(30). Briefly, the liver was first perfused with Ca2+/Mg2+-free HBSS 
containing 10 mM glucose, 10 mM HEPES, and 0.3 mM EDTA 
and then with HBSS containing 0.05% collagenase type IV 
(#C5138; Sigma-Aldrich), 1.3 mM CaCl2, 0.5 mM MgCl2, 10 mM 
glucose, and 10 mM HEPES. Hepatocytes were washed three 
times by low speed centrifugation (50 g for 2 min) and cell viabil-
ity, assessed by trypan blue exclusion, was confirmed to be >94% 
prior to plating cells. Cells were plated onto 12-well plates pre-
coated with rat tail collagen (#354236; BD Biosciences, Bedford, 
MA) at a density of 2 × 105 cells/well and cultured at 37°C under 
5% CO2 in Williams’ Medium E (GIBCO) containing 10% fetal 
bovine serum (GIBCO), 2% penicillin-streptomycin, 1% sodium 
pyruvate, 1% l-glutamine, and 1% insulin-transferrin-selenium 
(GIBCO) overnight prior to lipidation assays.
HDL preparation
HDL (d = 1.063–1.21 g/ml) was isolated from mouse plasma by 
density gradient ultracentrifugation as described previously (31). 
HDL was dialyzed against 150 mM NaCl and 0.01% EDTA, sterile 
filtered, and stored under argon gas at 4°C. Protein concentra-
tions were determined by the method of Lowry et al (32). HDL 
purity and integrity were confirmed by SDS-PAGE (4–20% poly-
acrylamide SDS gels; Bio-Rad Laboratories, Hercules, CA) and 
nondenaturing gradient gel electrophoresis (NDGGE) in which 
HDL was electrophoresed on a 4–20% nondenaturing polyacryl-
amide gel (Bio-Rad Laboratories) for 3.5 h at 200 V and 4°C.
Mouse SAA and apoA-I purification
Mouse SAA and apoA-I were purified as described (12) from 
HDL isolated from mouse plasma collected 24 h after injection 
with 1.0–2.5 g/g body weight LPS. Briefly, 20 mg of HDL were 
delipidated with ethanol:ether (3:2) and the delipidated proteins 
were separated by gel filtration on a Sephacryl S-200 column in 
buffer containing 7 M urea, 20 mM Tris, 150 mM NaCl, and 1 mM 
EDTA (pH 8.4). apoA-I- and SAA-containing fractions were iden-
tified by SDS-PAGE, pooled separately, and dialyzed against 2 mM 
Tris, 15 mM NaCl, and 0.1 mM EDTA (pH 8.4) prior to 10-fold 
concentration. LPS contamination in purified apolipoprotein 
preparations was below the level of detection (ToxinSensorTM 
Chromogenic LAL Endotoxin assay kit, #L00350C; GenScript, Pis-
cataway, NJ).
Radioiodination of HDL and apolipoproteins
Mouse HDL, purified mouse SAA and apoA-I, human SAA (Bio-
Vision; #4324), human apoA-I (Meridian Life Science; #A95120H), 
and human apoA-II (Meridian Life Science; #A50216H) were 
radiolabeled using the iodine monochloride method (33). The 
specific activity of 125I-SAA, 125I-apoA-I, 125I-apoA-II, and 125I-HDL 
ranged from 300 to 400 cpm/ng protein.
Ex vivo lipidation assays
To investigate the lipidation of endogenously produced SAA, 
primary hepatocytes were prepared from C57BL/6 mice 6 h after 
administration of 1 g/g LPS or 24 h after injection of 1 × 1011 
particles of an adenoviral vector expressing SAA (AdSAA) into 
SAA1.1/2.1/3-TKO mice. After an overnight culture, cells were 
treated with the LXR agonist T0901317 (5 M, #71810; Cayman 
Chemical) in Williams’ Medium E containing 0.2% fatty acid-free 
BSA for 8 h, as stated in the figure legends, to induce the expres-
sion of ABCA1. Cells were then cultured in medium containing 
0.2% fatty acid-free BSA for 4, 8, and 18 h in the absence of 
T0901317. To study exogenous SAA lipidation, primary hepato-
cytes were prepared from SAA1.1/2.1/3-TKO mice or apoA-I-
deficient mice, treated with 5 M T0901317 for 8 h, and then 
incubated for 4, 8, and 18 h with 10 g/ml purified mouse SAA in 
medium containing 0.2% fatty acid-free BSA. Cell lysates and cul-
ture media were harvested for analysis by SDS-PAGE and NDGGE 
followed by Western blotting. Alternatively, primary hepatocytes 
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from C57BL/6 mice, SAA1.1/2.1/3-TKO mice, or apoA-I-deficient 
mice were treated with T0901317 for 8 h and then incubated with 
125I-radiolabeled human apoA-I (5 g/ml, 0.177 M), apoA-II (10 
g/ml, 0.575 M), or SAA (10 g/ml, 0.870 M) for 16 h. Ali-
quots of cell media were separated by NDGGE, and dried gels 
were subjected to autoradiography.
Gel electrophoresis and Western blot analysis
Total cell lysates (10 g protein) or culture media (7 l) were 
separated by 4–20% SDS-PAGE and transferred to PVDF mem-
branes for immunoblotting. The amount of cell lysate and condi-
tioned media typically corresponded to approximately 3.8% and 
1.4% of the total amount in the dish, respectively. The following 
primary antibodies were used: rabbit anti-mouse SAA (1:2,000) 
(#ab199030; Abcam); rabbit anti-mouse SAA (12) (1:2,000); rab-
bit anti-mouse apoA-I (1:2,000) (#K23001R; Meridian Life Sci-
ence); rabbit anti-mouse SR-BI (1:1,000) (#NB400-104; Novus 
Biologicals, Littleton, CO); or rabbit anti-mouse ABCA1 (1:1,000) 
(#ab7360; Abcam). For loading controls, membranes were immu-
noblotted with anti--actin antibody (#A5441; Sigma-Aldrich). 
Secondary antibodies were peroxidase-conjugated anti-rabbit IgG 
(#A6154; Sigma-Aldrich) or anti-mouse IgG (#A4416; Sigma-Al-
drich). Immunoblots were visualized by the Amersham™ ECL™ 
Western blotting detection reagents (#RPN2106; GE Healthcare, 
Pittsburgh, PA).
To assess the lipidated species generated by primary mouse he-
patocytes, aliquots of culture media were electrophoresed on 
4–20% nondenaturing gradient gels for 3.5 h at 200 V and 4°C 
and transferred to PVDF membranes (40 min at 100 V, 4°C) for 
subsequent Western blotting or autoradiography. A protein stan-
dard mix containing proteins with known diameter (7.1, 8.2, 10.4, 
12.2, and 17.0 nm) was obtained from GE Healthcare (HMW Cali-
bration Kit for Native Electrophoresis, #17-0445-01) and used to 
estimate the sizes of lipidated species after separation by NDGGE.
Cell association and degradation of HDLs and SAA
Cell association of iodinated mouse HDLs, SAA, and apoA-I 
was assessed as described previously (34). Hepatocytes were 
seeded into 12-well cell culture clusters at a density of 2 × 105 
cells/well and then cultured overnight. After 8 h without or with 
T0901317 treatment, cells were washed with PBS and incubated at 
37°C for the indicated times with 5 g/ml 125I-SAA, 5 g/ml 125I-
apoA-I, or 10 g/ml 125I-HDL in Williams’ Medium E containing 
0.2% fatty acid-free BSA. At the end of the experiments, media 
were collected into glass tubes for degradation analysis. The cells 
were washed four times with cold PBS containing BSA (1 mg/ml) 
followed by two washes in the same buffer without BSA. The cells 
were then solubilized in 0.1 N NaOH for 60 min at room tem-
perature, and the protein concentration was determined by the 
method of Lowry et al. (32). The 125I content of cell lysates was 
determined in a  counter.
For analysis of cell-mediated 125I-HDL degradation, 500 l of 
BSA in PBS (1 mg/ml) and 400 l of 50% trichloroacetic acid 
were added to 500 l of media in glass tubes and mixed thor-
oughly. The mixture was stored at 4°C for at least 30 min or up to 
3 days. After centrifugation at 800 g and 4°C for 20 min, 1 ml of 
supernatant was moved to a new glass tube and 20 l of freshly 
made 20% KI were added and mixed, and then 50 l of 30% 
H2O2 were added and mixed. After incubation at room tempera-
ture for 5 min, 2 ml of chloroform were added to the mixture and 
vortexed thoroughly until the aqueous layer was clear. After cen-
trifugation at 800 g for 5 min, 750 l of the top layer was placed in 
a new tube and counted in a  counter.
For analysis of cell-mediated 125I-SAA and 125I-apoA-I degrada-
tion, culture media collected at the indicated times were applied 
to an Amicon Ultra 3K device and the flow-through samples con-
taining the degradation products were collected and counted in a 
 counter. It is possible that degradation products of SAA and 
apoA-I larger than 3,000 were retained in the column, resulting in 
an underestimate of apolipoprotein degradation. We opted to use 
this method of assessing degradation because the conventional 
method [i.e., quantifying trichloroacetic acid-soluble 125I counts] 
failed to produce meaningful results due to substantial precipita-
tion of the 125I-SAA peptide fragments.
Statistical analysis
Results are expressed as the mean ± SEM as indicated in the 
figure legends. Statistics were calculated with GraphPad’s Prism 5 
software. Comparisons of multiple groups were performed using 
one-way ANOVA or two-way ANOVA with Bonferroni’s multiple 
comparison tests. P-values less than 0.05 were considered statisti-
cally significant and denoted in figures with a single asterisk (*); 
P-values less than 0.01 and 0.001 were denoted with two (**) and 
three asterisks (***), respectively.
RESULTS
During an acute inflammatory response, SAA is synthe-
sized primarily in the liver and secreted into the circula-
tion, where it is found mainly associated with HDL. 
Whether SAA incorporates into HDL during HDL biogen-
esis or through a separate process is not known, and was 
the focus of this study. SAA expression was induced in 
C57BL/6 mice by injecting LPS 6 h prior to the prepara-
tion of hepatocytes, which allowed for robust SAA expres-
sion and secretion throughout the 18 h ex vivo experiments 
(Fig. 1A). As expected, no immunoreactive SAA was de-
tected in conditioned media or cell lysates of hepatocyte 
cultures prepared from SAA1.1/2.1/3-TKO mice (Fig. 1A, 
lanes 1 and 5). Cell culture media were subjected to 
NDGGE and immunoblotted to assess the lipidation state 
of the secreted SAA (Fig. 1B; lanes 1–6). This analysis indi-
cated that SAA is efficiently lipidated to form a number of 
discrete species ranging from 8.2 to 17 nm in diameter; 
no lipid-free SAA was detected in the culture media at any 
of the time points. Notably, the larger (12 and 17 nm) 
particles were predominant during the earlier time inter-
vals, suggesting that smaller species are not converted to 
larger species during the course of the incubations.
To study endogenous SAA lipidation in the absence 
of inflammation, an adenoviral vector expressing SAA 
(AdSAA) was injected into SAA1.1/2.1/3-TKO mice 24 h prior 
to the preparation of hepatocyte cultures. As shown in Fig. 
1C, SAA expression was sustained in primary hepatocytes 
from AdSAA-administered mice and accumulated in the 
culture media in a time-dependent fashion. Most of the 
SAA secreted by AdSAA-transduced hepatocytes was lipi-
dated (Fig. 1B; supplemental Fig. S1, lanes 7–9), forming 
species that appeared to be qualitatively similar to the lipi-
dated SAA species produced by hepatocytes undergoing an 
acute inflammatory response. At the doses administered, 
AdSAA provided markedly higher levels of secreted SAA 
compared with LPS, and resulted in the appearance of a 
portion of lipidated SAA that was smaller in size (7.5 nm) 
and thus likely relatively lipid poor. Taken together, these 
results suggest that the lipidation of endogenously expressed 
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SAA is not markedly influenced by inflammatory signaling 
in the liver, but can be overwhelmed in circumstances 
where SAA secretion is extremely high.
We next investigated to determine whether the lipida-
tion of exogenous SAA by mouse hepatocytes is distinctly 
different from the lipidation of secreted endogenously ex-
pressed SAA. Primary hepatocytes from SAA1.1/2.1/3-TKO 
mice were incubated with purified mouse SAA. Cell lysates 
and culture media were collected after 4, 8, or 18 h, sepa-
rated by SDS-PAGE, and analyzed by Western blotting. In-
terestingly, exogenously added SAA was readily detected in 
cell lysates at each of the time points, whereas SAA in the 
media disappeared during the 18 h time course (Fig. 1D). 
To determine the lipidation status of extracellular SAA, ali-
quots of culture media were separated by NDGGE followed 
by Western blotting (Fig. 1B, lanes 10–12). Based on the 
migration of immunopositive species, exogenously added 
SAA was lipidated to form species corresponding to endog-
enously expressed SAA, ranging from 7.5 to 17.0 nm in 
diameter. However, unlike secreted SAA, which accumu-
lated in the culture media over time, exogenously added 
SAA appeared to disappear from the media as both lipi-
dated and lipid-poor forms.
To investigate whether the disappearance of exogenous 
SAA from conditioned media is due to cell uptake, he-
patocytes were incubated with 5 g/ml 125I-SAA for cell 
association and degradation assays. An additional set of 
hepatocytes was incubated with 5 g/ml 125I-apoA-I for 
comparison. In the case of SAA, 6.3% and 2.4% of the 
apolipoprotein added to the dish was found cell-associated 
after 4 and 30 h, respectively (Fig. 2A), and this decrease 
in cell-associated SAA was accompanied by an accumula-
tion of degraded SAA in the culture media (Fig. 2B). In 
contrast, only 3.1% of apoA-I added to the dish was cell 
associated at 4 h, and the amount of cell-associated apoA-I 
remained relatively constant throughout the 30 h incuba-
tion (Fig. 2A). The amount of apoA-I degradation prod-
ucts in the media after 30 h was 4-fold lower compared 
with SAA (Fig. 2B). Taken together, these results suggest 
that hepatocytes take up and degrade SAA to a signifi-
cantly greater extent compared with apoA-I. To visualize 
the lipidation and degradation status of extracellular 125I-
SAA, conditioned media were separated by NDGGE fol-
lowed by autoradiography (Fig. 2C). At the 4 and 8 h time 
points, a predominant 8.2 nm species was apparent that 
likely corresponds to a major lipidated SAA species de-
tected by immunoblotting (Fig. 1B). At the later time 
points (18 and 30 h), this 8.2 nm species disappeared co-
incidentally with the accumulation of SAA degradation 
products (Fig. 2B, C). Our results suggest that exogenous 
SAA is efficiently lipidated by hepatocytes, but the lipi-
dated products are labile, due at least in part to hepatocyte 
uptake and degradation.
Because plasma SAA is mainly associated with HDL 
and not lipid free, the finding that SAA appears to be 
taken up and degraded more readily by hepatocytes than 
Fig. 1. Hepatocytes efficiently lipidate endogenous and exogenous SAA. A, C, D: SAA content of condi-
tioned media and cell lysates from primary hepatocyte cultures. Mouse primary hepatocytes were prepared as 
described in the Materials and Methods and, after overnight culture, were treated with 5 M T0901317 to 
induce ABCA1 expression, and then cultured in medium containing 0.2% fatty acid-free BSA. Conditioned 
media (7 l) and cell lysates (10 g protein) were collected at the indicated times were separated by SDS-
PAGE followed by Western blotting to detect SAA with -actin as loading control for cell lysates. A: Hepato-
cytes were prepared from untreated SAA1.1/2.1/3-TKO mice and C57BL/6 (C57) mice 6 h after injection of 
1 g/g body weight LPS. The results shown are representative of three immunoblots. B: Cell media from A, 
C, and D were subjected to NDGGE followed by Western blotting to detect SAA. The migration of size stan-
dards and lipidated SAA are indicated. The results shown are representative of two separate immunoblots. 
Note that a lower exposure of this immunoblot is presented in supplemental Fig. S1. C: Hepatocytes were 
prepared from untreated SAA1.1/2.1/3-TKO mice or SAA1.1/2.1/3-TKO mice 24 h after administration of 
1 × 1011 AdSAA. The results are representative of three immunoblots. D: Hepatocytes from untreated 
SAA1.1/2.1/3-TKO mice were incubated without or with 10 g/ml purified mouse SAA; the results are rep-
resentative of three immunoblots.
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apoA-I prompted us to assess hepatocyte metabolism of 
125I-HDL with and without SAA enrichment. 125I-HDLs 
were prepared using plasma collected from untreated 
C57BL/6 mice (C57-C HDL) and from C57BL/6 and 
SAA1.1/2.1-DKO mice 24 h after LPS injection (C57-LPS 
HDL and SAADKO-LPS HDL, respectively). Based on 
Coomassie staining after SDS-PAGE, we estimated that 
SAA comprised 30% of total apolipoproteins in C57-
LPS HDLs, whereas SAA was undetectable in C57-C and 
SAADKO-LPS HDLs (data not shown). Primary hepato-
cytes from C57BL/6 mice were incubated at 37°C for 4 h 
with the 125I-labeled HDLs. As shown in Fig. 3A, there was 
a significant increase (3.5-fold) in cell association of 
125I-C57-LPS HDL compared with C57-C HDL, which was 
accompanied by a significant 8-fold increase in degrada-
tion (Fig. 3B). Notably, this increase in cell association 
and degradation was totally abrogated for 125I-SAADKO-
LPS HDL, suggesting that SAA largely accounts for the 
observed increase in the association with hepatocytes 
and subsequent degradation of C57-LPS HDL compared 
with C57-C HDL. The increase in the cell association and 
degradation of 125I-C57-LPS HDL compared with the 
other HDLs could reflect either uptake and degradation 
of the entire 125I-labeled particle or selective uptake and 
degradation of the HDL-associated SAA.
Several studies have implicated SR-BI in mediating cho-
lesterol efflux to SAA (35, 36), as well as SAA uptake and 
clearance (25, 37). To investigate whether SAA lipidation is 
dependent on SR-BI, primary hepatocytes were prepared 
from SR-BI+/+ and SR-BI/ mice and then incubated with 
exogenously added mouse SAA. Western blotting confirmed 
SR-BI expression only in cells expressing SR-BI, and there 
was no evidence that incubations with SAA altered hepato-
cyte expression of SR-BI (Fig. 4A, top panel). It also did 
not appear that the lack of SR-BI reduced the amount of 
exogenous SAA associated with hepatocytes as assessed by 
Fig. 2. Exogenous SAA is degraded by hepatocytes to a greater 
extent than apoA-I. Primary hepatocytes were prepared from 
SAA1.1/2.1/3-TKO mice as described in the Materials and Methods 
and incubated at 37°C for the indicated times with 5 g/ml 125I-SAA 
or 125I-apoA-I. A: After removing the culture media, cells were solu-
bilized in 0.1 N NaOH, and the protein and 125I contents of the ly-
sates were determined and expressed as the percentage of the total 
amount of 125I added to the dish. B: The cell-mediated degradation 
of SAA and apoA-I was measured in the culture media and ex-
pressed as the percentage of the total amount of 125I added to the 
dish. Statistical analysis was performed using two-way ANOVA with 
Bonferroni’s multiple comparison tests. P-values less than 0.05 and 
0.001 are denoted with one (*) and three asterisks (***), respec-
tively. C: Aliquots of the cell media at each time point were sepa-
rated by NDGGE followed by autoradiography to visualize lipidated 
and degraded SAA. The migration of size standards, lipidated SAA, 
lipid-free SAA, and SAA degradation products are indicated.
Fig. 3. SAA increases HDL association and degradation in hepa-
tocytes. HDLs were prepared from untreated C57BL/6 mice and 
C57BL/6 and SAA1.1/2.1-DKO mice 24 h after LPS injection. The 
HDLs were radioiodinated and then incubated with primary hepa-
tocytes from C57BL/6 mice for 4 h at 37°C (10 g HDL protein per 
milliliter). Cell association (A) and degradation (B) were deter-
mined as described in the Materials and Methods and expressed as 
nanograms of HDL protein per milligram of cell protein. Values 
shown are the mean and SEM of triplicate determinations. Statisti-
cal analysis was performed using one-way ANOVA with Bonferroni’s 
multiple comparison tests. P-values less than 0.01 and 0.001 are de-
noted with two (**) and three asterisks (***), respectively.
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Western blotting of cell lysates after the 18 h incubation 
(Fig. 4A, middle panel; compare lanes 3–4 and 7–8). To in-
vestigate the impact of SR-BI deficiency on SAA lipidation, 
culture media were separated by NDGGE and immunob-
lotted with anti-SAA antibody (Fig. 4B). In this and some 
other studies, an immunoreactive species with an apparent 
diameter 12 nm was detected even in samples lacking 
SAA. The identity of this species is unknown. As shown in 
Fig. 4B, the lipidation of exogenous SAA by SR-BI/ hepa-
tocytes was not markedly altered compared with SR-BI+/+ 
hepatocytes, suggesting that SAA lipidation is not depen-
dent on SR-BI.
As indicated in the figure legends, hepatocyte cultures 
were preincubated with the LXR agonist T0901317 to in-
duce the expression of ABCA1, which we have shown sig-
nificantly increases cholesterol efflux and lipidation of 
apoA-I by primary mouse hepatocytes (38). To investigate 
whether SAA lipidation is dependent on ABCA1, primary 
hepatocytes were prepared from C57BL/6 and ABCA1-KO 
mice and incubated with purified mouse SAA without and 
with pretreatment with LXR agonist. As expected, ABCA1 
expression was detected only in C57BL/6 cells, where it was 
dramatically induced by LXR agonist (Fig. 5A). As shown in 
Fig. 5B, exogenous SAA was efficiently lipidated by hepato-
cytes from C57BL/6 mice but not ABCA1-KO mice, and 
induction of ABCA1 by LXR agonist was associated with an 
increase in the number and size of lipidated SAA species. 
Thus, the lipidation of SAA is clearly dependent on ABCA1.
We next investigated whether SAA expression alters the 
lipidation of mouse apoA-I. In particular, we were inter-
ested in determining whether both SAA and apoA-I incor-
porate into the same nascent particles. For these studies, 
primary hepatocytes were prepared from C57BL/6 mice 
24 h after injection of AdSAA or Adnull as negative control. 
After 8 h incubation with T0901317, cells were incubated 
with mouse apoA-I for 16 h. Cell media were separated by 
NDGGE followed by Western blotting to determine the 
lipidation status of SAA and apoA-I (Fig. 6A, B). While lipi-
dated SAA was more readily detected in conditioned media 
from hepatocytes transduced with AdSAA compared with 
Adnull, the size of the lipidated species generated by SAA-
overexpressing cells compared with control cells appeared 
to be qualitatively similar (Fig. 6A). Treatment with the 
LXR agonist enhanced the generation of lipidated SAA 
species by both sets of cells, consistent with a role for 
ABCA1 in this process. Importantly, overexpression of SAA 
in hepatocytes did not alter the amount or size distribution 
of lipidated species containing apoA-I (Fig. 6B). This find-
ing along with the observation that the lipidated products 
containing apoA-I compared with SAA appear to be dis-
tinct in size (compare Fig. 6A and B) strongly indicate that 
the two apolipoproteins are not present on the same na-
scent particles.
As another approach to investigate the relationship be-
tween the lipidation of SAA and other HDL apolipopro-
teins, primary hepatocytes prepared from C57BL/6 mice 
Fig. 4. Hepatocyte lipidation of SAA is not depen-
dent on SR-BI. Primary hepatocytes from SR-BI+/+ and 
SR-BI/ mice were incubated without or with 10 g/
ml purified mouse SAA for 18 h in the absence of 
T0901317 treatment. A: Cell lysates (20 g protein) 
were separated by SDS-PAGE followed by Western blot-
ting to detect SAA and SR-BI; -actin was assessed for 
loading control. B: Cell media (18 l) were separated 
by NDGGE followed by Western blotting to determine 
the lipidation status of SAA. The results shown are rep-
resentative of two independent experiments and two 
separate immunoblots. The migration of size stan-
dards and lipidated SAA species are indicated.
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were incubated with 125I-radiolabeled human apoA-I, 
apoA-II, or SAA for 16 h. Cell media were then separated 
by NDGGE followed by autoradiography to allow for di-
rect comparison of the lipidated species containing each 
apolipoprotein. As shown in Fig. 6D, 125I-apoA-I was asso-
ciated with particles primarily 7.4 and 10.0 nm in di-
ameter, whereas the major species containing 125I-apoA-II 
was 8.2 nm in diameter. In contrast, SAA-containing 
lipidated species comprised particles with sizes ranging 
from 8.2 to 12.2 nm in size. The discrepancy in the size 
distribution of the apoA-I, apoA-II, and SAA species indi-
cates that the apolipoproteins are lipidated indepen-
dently of one another, and provides evidence that SAA is 
not incorporated into apoA-I-containing HDL during 
HDL biogenesis.
To provide additional evidence that hepatocytes do 
not generate nascent particles containing both apoA-I 
and SAA, we performed experiments using hepatocytes 
isolated from apoA-I-deficient (AIKO) and SAA-deficient 
(TKO) mice that lack the ability to form lipidated parti-
cles containing both SAA and apoA-I endogenously pro-
duced. After 8 h incubation with T0901317, cells were 
incubated for 16 h with mouse apoA-I (10 g/ml) in the 
absence or presence of mouse SAA (10 g/ml), and then 
aliquots of conditioned media were separated by NDGGE 
followed by Western blotting to visualize lipidated spe-
cies containing SAA and/or apoA-I (Fig. 7A, B). In both 
AIKO and TKO hepatocytes, the presence of exogenous 
SAA did not alter the amount or size distribution of lipi-
dated species containing apoA-I (Fig. 7B), as would be 
expected if the two apolipoproteins were incorporated 
on the same nascent HDLs. As another approach, we 
also incubated AIKO and TKO hepatocytes with 125I-
radiolabeled mouse SAA (10 g/ml), mouse apoA-I 
(10 g/ml), or a mixture of both 125I-SAA and 125I-apoA-I 
for 16 h, and then visualized lipidated species by autora-
diography (Fig. 7C). Strikingly, the major lipidated spe-
cies observed when only apoA-I was present (7.4 and 
10 nm) were not shifted in size with the addition of 
SAA. Similarly, the polydisperse species containing only 
SAA (8.2–12.2 nm) appeared to be unaltered in the 
presence of apoA-I. These data strongly indicate that the 
two apolipoproteins are not present on the same nascent 
particles.
Fig. 5. Hepatocyte lipidation of SAA is dependent on ABCA1. 
Primary hepatocytes from C57BL/6 (C57) and ABCA1-deficient 
(ABCA1KO) mice were treated without or with T0901317 (5 M) 
for 8 h, and then incubated in the presence or absence of 10 g/
ml mouse SAA for 18 h, as indicated. A: Cell lysates were analyzed 
by SDS-PAGE followed by Western blotting for ABCA1 expression; 
-actin was assessed for loading control. B: Cell media were separated 
by NDGGE and then analyzed by Western blotting to determine 
the lipidation status of SAA. The results shown are representative 
of three independent experiments and three separate immunob-
lots. The migration of size standards and lipidated SAA species are 
indicated.
Fig. 6. Endogenous SAA expression does not alter 
the lipidation of apoA-I. A, B: Primary hepatocytes 
were prepared from C57BL/6 mice 24 h after injec-
tion of 1 × 1011 particles AdNull or AdSAA. After 8 h 
incubation without or with T0901317 (5 M), cells 
were incubated with mouse apoA-I (10 g/ml) for 16 h. 
Cell media were separated by NDGGE followed by 
Western blotting to determine the lipidation status of 
SAA (A) and apoA-I (B). The migration of size stan-
dards and lipidated apoA-I and SAA species are indi-
cated. C: Cell lysates (20 g protein) were analyzed by 
SDS-PAGE followed by Western blotting for ABCA1 
expression; -actin was assessed for loading control. D: 
Primary hepatocytes from C57BL/6 mice were treated 
with 5 M T0901317 for 8 h and then incubated with 
125I-radiolabeled human apoA-I (5 g/ml), apoA-II 
(10 g/ml), or SAA (10 g/ml) for 16 h. Cell media 
were separated by NDGGE followed by autoradiogra-
phy. The migration of size standards and lipidated spe-
cies are indicated.
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DISCUSSION
The liver undergoes major reprogramming during an 
acute inflammatory response with a number of genes ei-
ther suppressed or induced. The most sensitive acute phase 
reactant is SAA, which may be transiently upregulated 
1,000-fold or more within 12–48 h after infection or tissue 
injury (1, 2). Acute phase SAA is present in virtually all ver-
tebrates studied and is highly conserved through at least 
500 million years of evolution, indicating that the induc-
tion of SAA plays an important survival role in a systemic 
inflammatory response (39, 40). The vast majority of SAA 
secreted by the liver is typically found associated with the 
HDL fraction in plasma; little or none is in a lipid-free form 
(22). Although it is now recognized that lipid-free and 
HDL-associated SAA are functionally distinct (23, 35, 36), 
the pathways leading to the association/disassociation of 
SAA with HDL are not clearly understood. Whether SAA-
containing HDL is formed through the modification of 
preexisting HDL or during the assembly of new HDL par-
ticles has not been conclusively established. In the present 
study, we demonstrate that HDL does not acquire SAA dur-
ing nascent HDL biogenesis. This data, coupled with our 
prior study demonstrating that SAA is an exchangeable 
apolipoprotein (22), provide new insights into SAA metab-
olism and the regulation of its function.
We focused on the interaction of SAA with hepatocytes, 
the primary site of HDL biogenesis. An important finding 
of our study is that SAA is lipidated by hepatocytes indepen-
dent of apoA-I. Based on their migration on nondenaturing 
gradient gels, these two apolipoproteins do not appear to 
be present on the same nascent particles. Whereas lipid-
poor apoA-I generated two distinct lipidated species 7.4 
and 10.0 nm in diameter, the lipidated SAA species were 
much more poly-disperse, ranging from 8.2 to 12.2 nm in 
size. Moreover, the apparent size of apoA-I-containing spe-
cies was not altered when SAA was also present, supporting 
the conclusion that the vast majority of SAA is not incorpo-
rated into apoA-I-containing particles during HDL biogen-
esis. Our results are similar to those of Abe-Dohme et al. 
(41), who characterized the size distribution of cholesterol- 
and phosphatidylcholine-containing particles present in 
conditioned media from HEK293 cells stably transfected to 
express ABCA1. Based on HPLC elution profiles, cells incu-
bated with apoA-I for 48 h formed two major species of lipi-
dated particles that differed in size compared with the 
dominant species formed when the cells were incubated 
with lipid-poor SAA. In another study, Cabana et al. (42) 
determined that apoA-I and SAA recovered from condi-
tioned media of McA RH777 rat hepatoma cell cultures by 
density gradient centrifugation were distributed in different 
density fractions. Our novel finding that the initial lipida-
tion of SAA does not give rise to particles containing both 
apoA-I and SAA raises interesting questions as to how SAA 
incorporates into the apoA-I-containing HDL fraction in 
vivo. It is known that SAA-containing HDL particles can be 
produced by the displacement of apoA-I on HDL by lipid-
free SAA (42), and that SAA can be exchanged between 
HDL and apoB-containing lipoproteins (22). Whether the 
lipidated species generated by ABCA1 efficiently incorpo-
rate into mature HDL particles, and whether this leads to 
the dissociation of apoA-I, requires further investigation.
We determined that SAA lipidation by hepatocytes does 
not occur in the absence of ABCA1. SAA contains two 
-helical regions and a short amphipathic -helix within 
the N-terminal portion that is thought to be involved in lipid 
binding, and thus appears to fulfill the structural require-
ments for ABCA1 efflux (39). The finding in the current 
study that ABCA1 is required for SAA lipidation is consis-
tent with previous studies in stably transfected HEK293 
cells (41) and primary hepatocytes isolated from mice af-
ter LPS injection (43). Furthermore, Hu et al. (43) showed 
that in the absence of ABCA1, SAA biosynthesis is induced 
in the liver after LPS administration, but it is not recovered 
in the plasma in a lipidated form, suggesting that there is 
no alternative pathway for SAA-HDL production in the ab-
sence of ABCA1. On the other hand, SAA “only” HDL can 
be detected in apoA-I-deficient mice injected with LPS (44, 
45), consistent with the biogenesis of SAA-containing par-
ticles that lack apoA-I. However, the formation of such 
Fig. 7. The presence of SAA does not alter the lipidation of apoA-I. 
Primary hepatocytes were prepared from apoA-I-deficient (AIKO) 
and SAA1.1/2.1/3-deficient (TKO) mice and treated with T0901317 
(5 M) for 8 h. A, B: Cells were incubated with mouse apoA-I (10 
g/ml) in the absence or presence of mouse SAA (10 g/ml) for 
16 h, as indicated. Cell media were separated by NDGGE followed 
by Western blotting to determine the lipidation status of SAA (A) 
and apoA-I (B). The results shown are representative of two immu-
noblots. The migration of size standards and lipidated SAA and 
apoA-I species are indicated. C: Cells were incubated with 125I-radio-
labeled mouse SAA (10 g/ml), 125I-radiolabeled mouse apoA-I (10 
g/ml), or a mixture of both (each at 10 g/ml) for 16 h. Cell 
media were separated by NDGGE followed by autoradiography. The 
results shown are representative of three gels. The migration of size 
standards and lipidated species are indicated.
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particles appears to rely on an unidentified component 
of the inflammatory response, because SAA expressed in 
the livers of apoA-I-deficient mice via adenoviral vector 
was found almost exclusively in the lipoprotein-free frac-
tion (46).
Our studies indicate that SAA is not lipidated by SR-BI, a 
high affinity receptor for SAA (37). However, we cannot 
rule out the possibility that SR-BI plays a role in the forma-
tion of HDL-associated SAA. According to a published 
study, lipid-free and lipid-poor SAA failed to stimulate cho-
lesterol efflux via SR-BI. However, SR-BI-mediated choles-
terol efflux did occur following extensive lipidation of SAA 
(35). Thus, the impact of the lipidation status of SAA on 
cholesterol mobilization by SR-BI appears to be similar to 
what has been observed for other amphipathic apolipopro-
teins, including apoA-I (47).
Kinetic studies in mice determined that SAA on HDL is 
cleared more rapidly from plasma than apoA-I (25, 48, 49). 
In the current study, we showed that exogenously added 
SAA associates with hepatocytes and is degraded by hepato-
cytes to a significantly greater extent compared with apoA-I. 
Thus, SAA is efficiently lipidated by hepatocytes, but the 
lipidated products are labile, possibly due to hepatocyte up-
take and degradation. It is also possible that hepatocytes 
secrete a soluble protease capable of degrading extracellu-
lar SAA. However, results from mixing experiments in 
which SAA was incubated with hepatocyte-conditioned me-
dia indicate that the degradation of SAA is cell dependent 
(data not shown). Thus, available data suggests that SAA is 
either degraded inside the cell and resecreted, or is de-
graded by a protease that is tethered on the hepatocyte cell 
surface. We also showed that the presence of SAA increases 
the association and subsequent degradation of radioiodin-
ated HDL by hepatocytes, consistent with the notion that 
SAA is selectively dissociated from the HDL particle by 
hepatocytes.
Notably, the uptake/degradation of SAA was not mark-
edly altered in hepatocytes lacking SR-BI. This finding 
aligns with our previous report demonstrating that al-
though the in vivo clearance rate of SAA was reduced in 
mice lacking SR-BI, it remained significantly faster com-
pared with that of apoA-I, indicating a relatively minor 
role of SR-BI in SAA’s rapid clearance (25). However, the 
current studies appear to be in conflict with a previous 
study identifying human SR-BII as a functional SAA recep-
tor that mediates uptake of lipid-free SAA (50), because 
the SR-BI/ mice used in the present study also lack SR-
BII, an mRNA splicing variant of SR-BI that contains an 
alternative C-terminal cytoplasmic tail (51, 52). The dis-
crepant conclusions regarding the role of SR-BII in SAA 
metabolism from the two studies may be due to differences 
in experimental approaches (loss-of-function versus gain-
of-function), cell systems (primary mouse hepatocytes 
versus transfected HeLa cells), or species differences (mouse 
versus human SR-BII). Clearly, additional studies are 
needed to investigate the pathway(s) by which hepatocytes 
take up and degrade SAA in all of its lipidated forms.
SAA has been shown to exert a number of biological ef-
fects consistent with its role in innate immunity and tissue 
repair, including leukocyte chemotaxis, inflammatory cyto-
kine induction, and upregulation of genes involved in ex-
tracellular matrix remodeling (15, 16, 20). Notably, these 
activities have been attributed to lipid-free SAA and are 
markedly abrogated when SAA is associated with HDL (19, 
23, 24). Like lipid-free apoA-I, lipid-free SAA seems to be 
removed rapidly from the extracellular space by an un-
known mechanism in vivo, as it does not accumulate in 
plasma. Because lipid-free SAA is cleared more rapidly 
than HDL-bound SAA (48), it is possible that the main pur-
pose for SAA’s association with HDL is to prolong its life in 
the circulation and to regulate its pro-inflammatory effects 
during an acute phase response.
In summary, SAA is lipidated by hepatocytes in an 
ABCA1-dependent manner to form nascent particles that 
are distinct from apoA-I-containing particles, indicating 
that SAA is not incorporated into HDL during HDL bio-
genesis. These findings provide new insights into SAA me-
tabolism and the regulation of its function.
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